Tag: GWPH

GW Pharma Epidiolex FDA Decision Date Set for June 27th

GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) —...
- December 28th, 2017 at 7:25 am

GW Pharma Closes $317.4 Million Equity Offering

GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs Raising Gross Proceeds of $317.4 Million and Full Exercise of Underwriter’s Option to Purchase Additional ADSs LONDON, UK,...
- December 12th, 2017 at 6:37 am

GW Pharma to Raise up to $258.75 Million in Underwritten Deal

GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON, Dec. 05, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPRF) (Nasdaq:GWPH) (“GW” or the “Company”), a biopharmaceutical company focused on...
- December 5th, 2017 at 4:38 pm

GW Pharma Expects FDA Decision on Epidiolex in Mid-2018

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress Epidiolex® (cannabidiol) NDA Submitted to FDA Conference call today at 7:30 a.m. EST LONDON...
- December 4th, 2017 at 7:42 am

Cannabis ETF Makes Changes After Index Rebalancing

Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ) (OTC: HMLSF), the world’s first and still only cannabis ETF, has adjusted its portfolio this month as its benchmark, the North...
- September 20th, 2017 at 9:30 am

Overexposed Cannabis ETF Hit Hard by Biotech Losses

Horizons Marijuana Life Sciences Index ETF (TSX: HMMJ) (OTC: HMLSF) has been hit hard over the past two weeks, declining 8.4% since July 26th despite what has been a stable market...
- August 9th, 2017 at 12:46 pm

Horizons Medical Marijuana ETF to Debut April 5th

Let’s face it, when it comes to cannabis stocks, Canada continues to crush the United States, where federal illegality makes it more difficult to operate and to raise capital....
- April 2nd, 2017 at 11:14 pm

GW Pharma Reports FY17-Q1 Financials

GW Pharmaceuticals plc Reports First Quarter 2017 Financial Results and Operational Progress Epidiolex® NDA submission and launch preparation on track New Positive Phase 2 glioma data further demonstrates value...
- February 7th, 2017 at 8:44 am

GW Pharma Ends FY16 with $483mm in Cash

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress – Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – – NDA submission...
- December 5th, 2016 at 7:52 am

GW Pharma Progresses Towards Epidiolex FDA Submission

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
- December 5th, 2016 at 7:39 am